LINK WILLIAM J PHD — SEC insider filings
SEC reporting owner CIK 1228684. 55 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers the 50 most recent of 55 filings on record, filed 2021-05-14 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 31,250 shares, $500,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 22 legs across 8 filings — 700,812 shares, $16,503,166 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 78.
- Largest priced transaction: sale of 303,614 shares @ $14.63 ($4,442,693) in Oyster Point Pharma, Inc., filed 2021-10-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Oyster Point Pharma, Inc. (OYST) | Director | 5 | — | 4 legs · 550,000 sh · $8,160,736 | 8 |
| Tarsus Pharmaceuticals, Inc. (TARS) | Director | 21 | — | 16 legs · 122,562 sh · $6,939,309 | 37 |
| RxSight, Inc. (RXST) | Director | 17 | 1 leg · 31,250 sh · $500,000 | 2 legs · 28,250 sh · $1,403,120 | 24 |
| LENSAR, Inc. (LNSR) | Director | 6 | — | — | 8 |
| GLAUKOS Corp (GKOS) | Director | 1 | — | — | 1 |
Insider filings — LINK WILLIAM J PHD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 201 · Sale (S): 11,675 @ $78.33 · Sale (S): 759 @ $79 · Sale (S): 66 @ $80.01 · Option exercise (M): 201 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 806 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 37,037 | EDGAR |
| 2026-06-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 10,572 @ $61.97 · Sale (S): 1,928 @ $62.94 | EDGAR |
| 2026-06-16 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LENSAR, Inc. (LNSR) | Grant/award (A): 17,421 @ $0 | EDGAR |
| 2026-03-18 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 3,629 @ $68.09 · Sale (S): 8,378 @ $69.03 · Sale (S): 493 @ $69.75 | EDGAR |
| 2025-12-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 5,046 @ $80.80 · Sale (S): 6,306 @ $81.75 · Sale (S): 1,148 @ $82.39 · Sale (S): 5,680 @ $80.71 · Sale (S): 4,766 @ $81.50 | EDGAR |
| 2025-09-18 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Gift (G): 2,000 @ $0 | EDGAR |
| 2025-09-10 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 27,116 @ $57 | EDGAR |
| 2025-06-16 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 3,350 · Grant/award (A): 4,540 (derivative) @ $0 · Grant/award (A): 2,954 (derivative) @ $0 · Option exercise (M): 3,350 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 10,752 | EDGAR |
| 2025-05-28 | 4 | LENSAR, Inc. (LNSR) | Grant/award (A): 7,374 @ $0 | EDGAR |
| 2024-08-14 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Other (J): 74,892 @ $0 · Other (J): 10,446 @ $0 · Other (J): 27,116 @ $0 · Sale (S): 29,979 @ $26.01 · Sale (S): 5,021 @ $26.53 | EDGAR |
| 2024-06-25 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 3,350 · Option exercise (M): 3,350 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 3,350 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 2,554 | EDGAR |
| 2024-05-09 | 4 | LENSAR, Inc. (LNSR) | Grant/award (A): 22,000 @ $0 | EDGAR |
| 2024-02-02 | 4 | RxSight, Inc. (RXST) | Sale (S): 20,598 @ $49.54 · Sale (S): 7,652 @ $50.01 · Gift (G): 3,000 @ $0 | EDGAR |
| 2023-08-18 | 4 | RxSight, Inc. (RXST) | Other (J): 694,124 @ $0 · Other (J): 2,610 @ $0 · Other (J): 21,248 @ $0 | EDGAR |
| 2023-06-26 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 3,350 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 5,731 @ $0 | EDGAR |
| 2023-05-30 | 4 | LENSAR, Inc. (LNSR) | Grant/award (A): 9,288 @ $0 · Grant/award (A): 33,175 (derivative) @ $0 | EDGAR |
| 2023-05-15 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Other (J): 215,576 @ $0 · Other (J): 41,219 @ $0 | EDGAR |
| 2023-05-12 | 4 | RxSight, Inc. (RXST) | Other (J): 258,390 @ $0 · Other (J): 98,715 @ $0 | EDGAR |
| 2023-03-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Other (J): 215,575 @ $0 · Other (J): 52,194 @ $0 | EDGAR |
| 2022-11-14 | 4 | RxSight, Inc. (RXST) | Other (J): 316,694 @ $0 · Other (J): 107,236 @ $0 | EDGAR |
| 2022-11-14 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Other (J): 215,575 @ $0 · Other (J): 8,382 @ $0 | EDGAR |
| 2022-08-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Other (J): 215,575 @ $0 · Other (J): 3,749 @ $0 | EDGAR |
| 2022-08-11 | 4 | RxSight, Inc. (RXST) | Other (J): 316,694 @ $0 · Other (J): 107,236 @ $0 | EDGAR |
| 2022-07-01 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 7,000 (derivative) @ $0 · Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | RxSight, Inc. (RXST) | Other (J): 375,000 @ $0 · Other (J): 126,979 @ $0 | EDGAR |
| 2022-06-08 | 4/A | RxSight, Inc. (RXST) | Other (J): 126,979 @ $0 | EDGAR |
| 2022-06-08 | 4/A | RxSight, Inc. (RXST) | Other (J): 126,979 @ $0 | EDGAR |
| 2022-06-03 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 10,349 @ $0 | EDGAR |
| 2022-05-31 | 4 | LENSAR, Inc. (LNSR) | Grant/award (A): 4,285 @ $0 · Grant/award (A): 15,616 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | RxSight, Inc. (RXST) | Other (J): 375,000 @ $0 | EDGAR |
| 2022-03-17 | 4 | RxSight, Inc. (RXST) | Other (J): 375,000 @ $0 | EDGAR |
| 2022-01-07 | 4 | Oyster Point Pharma, Inc. (OYST) | Other (J): 6,438 @ $0 · Other (J): 401 @ $0 | EDGAR |
| 2021-12-23 | 4 | Oyster Point Pharma, Inc. (OYST) | Other (J): 6,438 @ $0 · Other (J): 400 @ $0 | EDGAR |
| 2021-11-16 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Other (J): 250,000 @ $0 · Other (J): 4,348 @ $0 | EDGAR |
| 2021-10-20 | 4 | Oyster Point Pharma, Inc. (OYST) | Sale (S): 303,614 @ $14.63 · Sale (S): 242,943 @ $15.09 · Sale (S): 1,912 @ $14.63 · Sale (S): 1,531 @ $15.09 | EDGAR |
| 2021-08-05 | 4 | RxSight, Inc. (RXST) | Conversion (C): 2,016,778 @ $0 · Purchase (P): 31,250 @ $16 · Conversion (C): 2,016,778 (derivative) @ $0 | EDGAR |
| 2021-08-02 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 5,859 @ $0 | EDGAR |
| 2021-06-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-09 | 4 | Oyster Point Pharma, Inc. (OYST) | Grant/award (A): 3,466 @ $0 · Grant/award (A): 5,199 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 2,382 @ $0 | EDGAR |
| 2021-05-20 | 4 | LENSAR, Inc. (LNSR) | Grant/award (A): 20,847 (derivative) @ $0 | EDGAR |
| 2021-05-14 | 4 | Oyster Point Pharma, Inc. (OYST) | Other (J): 10,302 @ $0 · Other (J): 642 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1228684 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs